Moments
Nine places the two lenses meet the investor
Each is written as a scene, not an endpoint. The chip says where the research places it.
A market tab on every portfolio company
Open a company and the market tab answers "What changed?": five important developments since the last visit; an updated competitor and ecosystem map; capital-flow charts and recent rounds; demand, hiring, customer, technical, and regulatory signals; changes to the TAM model or its assumptions; thesis-supporting and thesis-challenging evidence; unanswered questions and low-confidence areas; freshness and coverage by source family.
Each card shows why it was matched, the underlying source, observed date versus publication date, extraction confidence, and whether the conclusion is an observation or an inference. The market, refreshed, not frozen at the diligence memo.
Company Pulse beside it
At the top of the company page, a compact pulse in three sections: Company says, Others report, and Observed changes. It answers what happened since the last founder update, what is genuinely new since I last looked, whether there is anything to congratulate, ask about, help with, or watch, and which sources have gone stale or stopped publishing.
Provenance is legible at a glance. You know who said it before you read what they said.
"Since the last board meeting"
Before a board meeting, a compact briefing: material market events since the previous meeting; competitor moves most relevant to the company's current goals; new funding or M&A; regulatory deadlines or decisions; demand and customer-voice movement; suggested questions for the founder; changes that may affect the company's KPI benchmarks or fundraising story.
Suggested questions stay drafts. The investor decides whether "Competitor X launched a low-cost tier, are we seeing pricing pressure?" is relevant enough to ask. The product prepares. The investor asks.
"Brief me on Acme since our last call"
A meeting-prep request that combines external events with PostMoney's internal updates, metrics, tasks, and prior discussion. Digests synthesize rather than enumerate: top developments and why they may matter; momentum and risk themes supported by event clusters; questions for the next founder call; helpful actions the investor could take; source coverage and blind spots; a short appendix of everything collected.
Every external claim is cited, and private versus public evidence is labeled. One request, both lenses, no guessing about where a fact came from.
Living and point-in-time reports
Reports on request: market landscape and segment map; TAM/SAM/SOM model with scenarios; quarterly funding and M&A review; competitive feature and positioning analysis; regulatory and reimbursement outlook; customer-voice study; scientific, patent, or clinical-trial landscape; board-market briefing; LP-ready sector thesis update. On the company side, an event becomes a sourced milestone in a memo or LP report and keeps its original source link, event date, and provenance even if the wording is edited.
Every report has a clear as-of date and preserves a snapshot of its evidence and assumptions. A living dossier can update continuously; an investment committee memo must remain reproducible months later. Living where it should live, frozen where it must freeze.
Alerts designed around decisions
Watch a company, category, competitor set, geography, or thesis condition. Market examples: "A direct competitor raised more than $20 million." "Three competitors added the same integration in 60 days." "A relevant proposed rule entered its comment period." "Evidence contradicts an assumption in the saved TAM model." Company examples: "High confidence: the FDA posted a recall matching Acme's product identifier." "Acme announced a new channel partnership; four publications repeated the release." "The careers page added eight enterprise-sales roles across two regions." "Possible namesake match: an article mentions 'Acme Health' in Toronto. Review before adding." "Correction: the publication changed the reported funding amount from $18M to $12M."
Suppress duplicates, batch low-importance changes, and escalate only when a signal crosses an investor-defined threshold. A weekly digest is likely more valuable than real-time notifications for most evidence; a recall, regulatory deadline, or major financing may justify immediacy. Interrupt rarely, and only for something that changes a decision.
Monday portfolio radar
Across the market: multiple companies affected by the same regulation or platform change; overlapping competitors across the portfolio; common customer segments or channel partners; sector-level capital and demand trends; opportunities for introductions, bundling, procurement, or knowledge sharing; concentration risk hidden by different industry labels. Across companies: which launched products this quarter, which had meaningful press or regulatory milestones, where hiring is expanding or contracting, which have had no public or private update in 90 days, which externally observed events are not yet reflected in a founder update.
Organization-scoped watchlists reveal shared exposure that no single company page can show. Portfolio-level questions, answered on a Monday morning.
Ask Desk
Desk answers against the dossier and its evidence. Market questions: "Who are the fastest-growing independent-practice CRM competitors?" "What changed in this market since our Series A investment?" "Build a bottom-up TAM using U.S. specialty-practice counts." "What evidence argues against our thesis?" "Compare this founder's market claims with external evidence." Company questions: "What has the company itself claimed about enterprise demand, and what independent evidence supports it?" "What changed publicly after the last board deck?"
Answers distinguish sourced facts, calculated results, estimates, and interpretation, and the user can open the evidence behind every material claim. A research analyst who shows the footnotes.
Human curation everywhere
On the company side: confirm official accounts and legal identifiers; merge or split events; correct an entity match; promote an event to "portfolio milestone"; add context such as "we knew about this; not a risk"; suppress a source, topic, namesake, or repeated campaign; create a follow-up; request a watch on a newly discovered URL; see and undo what automation changed. On the market side: move companies between segments, add a missing niche, save alternate versions of the map, and choose the canonical observation when funding sources disagree.
These actions make the monitor improve for the organization without silently changing the shared global identity of the company. Automation proposes. People decide, and can undo.
A worked week
How the moments connect across six days
One investor, one portfolio, one week. Each step reuses a scene the research already describes.
This week is a synthesis of the two docs' own examples, stitched into a sequence to show how the pieces relate. It is an illustration, not a spec, and it adds no capability the docs do not describe.
Monday: the radar First shape
The Monday portfolio radar flags two companies affected by the same proposed rule, which has entered its comment period, and a direct competitor round above the investor's threshold. Both were watched conditions, so both surfaced without anyone searching.
Tuesday: observed changes First shape
A company's careers page adds eight enterprise-sales roles across two regions and its pricing page gains an enterprise plan. Pulse groups both under Observed changes, apart from anything the company or the press has said, because nobody has said anything yet.
Wednesday: before the board meeting First shape
The investor opens the market tab and requests the "since the last board meeting" briefing. It lists material market events since the previous meeting, the competitor moves most relevant to current goals, and two draft questions for the founder. The investor keeps one and discards the other.
Thursday: a correction First shape
A correction event arrives: the publication changed the reported funding amount from $18M to $12M. The draft memo that cited the earlier figure as a sourced milestone updates, and the item keeps its original source link, event date, and provenance.
Friday: promote and freeze First shape
The investor promotes a launch to "portfolio milestone" and requests an LP-ready sector thesis update. The report carries today's as-of date and a frozen snapshot of its evidence and assumptions, so it will read the same months from now while the dossier behind it keeps moving.
Next Monday: what changed since First shape
The radar returns to the same question with a new baseline: what changed since last Monday, which externally observed events are still not reflected in a founder update, and which companies have gone quiet.
Two illustrative reports
What a market report could actually say
The research sketches two reports for two very different companies. Each ends with the kind of insight a keyword feed would miss.
Consumer
Direct-to-consumer functional nutrition
For a protein beverage or functional-nutrition company: category boundaries across sports nutrition, meal replacement, supplements, weight management, and functional beverages; TAM scenarios by consumer population, purchase frequency, channel, and average selling price; a competitor map by format, ingredient, health claim, target consumer, price point, and distribution; retailer assortment, rank, promotion, review, and stockout movement; DTC traffic, search interest, subscription offers, paid creative, and creator partnerships; ingredient and claim regulation, recalls, warning letters, and emerging research; funding, celebrity-backed entrants, strategic CPG investment, and acquisitions; common customer complaints such as taste, texture, digestion, packaging, or price; a "why now / why not" narrative and key disconfirming evidence.
The investor might learn that the broad category is growing while the company's specific format is losing search share, or that retail distribution is expanding faster than DTC despite the original investment thesis.
Vertical software
CRM for doctors
For a vertical healthcare CRM: separate maps for independent practices, large physician groups, health systems, pharma-facing physician engagement, and patient acquisition; a bottom-up TAM based on eligible practices, provider counts, seats, locations, and realistic annual contract value; incumbent EHR and practice-management bundles, horizontal CRMs, point solutions, agencies, and manual substitutes; integrations, interoperability standards, privacy requirements, and security certifications; pricing and packaging changes; job growth in implementation, enterprise sales, compliance, and integrations; health-system procurement notices and implementation-partner activity; review themes around workflow, data migration, usability, and support; adjacent acquisitions by EHR, payer, and revenue-cycle vendors; regulatory developments affecting communication, consent, data exchange, or reimbursement.
The useful insight may be that the most dangerous competitor is not another "doctor CRM," but an EHR vendor bundling adequate CRM functionality into an existing contract.
Under the hood
What every experience shares
Surfaces
The company page's market tab and Pulse. A unified timeline with visually distinct lanes: founder and investor updates, verified first-party announcements, independent coverage and public records, inferred signals. Alerts and digests. Reports and report items. Desk. Organization-scoped watchlists.
Rules
Reports carry an as-of date and a snapshot of evidence and assumptions. Every card labels observation versus inference. Suggested questions remain drafts. Alerts are deduplicated, batched, and thresholded. Corrections propagate to anything that cited the earlier claim. Global evidence may be shared; watchlists, annotations, and thesis stay private to the organization.
Caveats
Alert fatigue is the failure mode: every item does not merit a notification. Digests synthesize rather than enumerate. The summary is a navigation aid, not a replacement for the source; the user should always be able to open the evidence behind a material claim. External estimates never silently become founder-reported data.
How confidence, provenance, and corrections work: Evidence & Trust →. Which of these belong in the smallest coherent product: Foundations →.